Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MAGE-A3/12 TCR Gene Therapy for Metastatic Cancer
NCT01273181Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Dec 2012
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PG13-MAGE-A3 TCR9W11 in metastatic cancer, melanoma, metastatic renal cell carcinoma (mRCC), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
PG13-MAGE-A3 TCR9W11
03
Conditions
metastatic cancermelanomametastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01273181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01273181.